

1 **Measuring change in trials of physical activity interventions: a comparison of self-report**
2 **questionnaire and accelerometry within the PACE-UP trial.**

3

4 Elizabeth S Limb¹, Shaleen Ahmad¹, Derek G Cook*¹, Sally Kerry², Ulf Ekelund³, Peter Whincup¹,
5 Christina R Victor⁴, Steve Iliffe⁵, Michael Ussher¹, Julia Fox-Rushby⁶, Cheryl Furness¹, Judith
6 Ibison¹, Stephen deWilde¹ Tess Harris¹

7

8 **Addresses**

9 Elizabeth S Limb elimb@sgul.ac.uk Population Health Research Institute, St George's University of
10 London, SW17 ORE, UK

11 Shaleen Ahmad shahmad@sgul.ac.uk Population Health Research Institute, St George's University
12 of London, SW17 ORE, UK

13 Derek G Cook* d.cook@sgul.ac.uk Population Health Research Institute, St George's University of
14 London, SW17 ORE, UK

15 Sally Kerry s.m.kerry@qmul.ac.uk Pragmatic Clinical Trials Unit, Queen Mary's University of
16 London, E1 2AT, UK

17 Ulf Ekelund ulf.ekelund@nih.no Department of Sport Medicine, Norwegian School of Sport
18 Sciences, PO Box 4014, 0806, Oslo, Norway.

19 Peter Whincup pwhincup@sgul.ac.uk Population Health Research Institute, St George's University
20 of London, SW17 ORE, UK

21 Christina R Victor christina.victor@brunel.ac.uk Gerontology and Health Services Research Unit,
22 Brunel University, London UB8 3PH, UK.

23 Steve Iliffe s.iliffe@ucl.ac.uk Research Department of Primary Care & Population Health, University
24 College, London, NW3 2PF, UK.

25 Michael Usher musscher@sgul.ac.uk Population Health Research Institute, St George's University of
26 London, SW17 ORE, UK

27 Julia Fox-Rushby julia.fox-rushby@kcl.ac.uk Department of Population Science, King's College
28 London, SE1 1UK, UK (current address).

29 Cheryl Furness cfurness@sgul.ac.uk Population Health Research Institute, St George's University of
30 London, SW17 ORE, UK

31 Judith Ibson jibison@sgul.ac.uk Population Health Research Institute, St George's University of
32 London, SW17 ORE, UK

33 Stephen de Wilde sdewilde@sgul.ac.uk Population Health Research Institute, St George's University
34 of London, SW17 ORE, UK

35 Tess Harris tharris@sgul.ac.uk Population Health Research Institute, St George's University of
36 London, SW17 ORE, UK

37

38 * Corresponding author

39 Derek G Cook Population Health Research Institute, St George's University of London, Cranmer
40 Terrace, Tooting, London, SW17 ORE, UK

41 d.cook@sgul.ac.uk

42

43

44

45

46

47

48

49

50 **Abstract**

51 **Background:** Few trials have compared estimates of change in physical activity (PA) levels using
52 self-reported and objective PA measures when evaluating trial outcomes. The PACE-UP trial offered
53 the opportunity to assess this, using the self-administered International Physical Activity
54 Questionnaire (IPAQ) and waist-worn accelerometry.

55 **Methods:** The PACE-UP trial (N=1023) compared usual care (n=338) with two pedometer-based
56 walking interventions, by post (n=339) or with nurse support (n=346). Participants wore an
57 accelerometer at baseline and 12 months and completed IPAQ for the same 7-day periods. Main
58 outcomes were weekly minutes, all in ≥ 10 minute bouts as per UK PA guidelines of: i) accelerometer
59 moderate-to-vigorous PA (Acc-MVPA) ii) IPAQ moderate+vigorous PA (IPAQ-MVPA) and iii)
60 IPAQ walking (IPAQ-Walk). For each outcome, 12 month values were regressed on baseline to
61 estimate change.

62 **Results:** Analyses were restricted to 655 (64%) participants who provided data on all outcomes at
63 baseline and 12 months. Both intervention groups significantly increased their accelerometry MVPA
64 minutes/week compared with control: postal group 42 (95% CI 22, 61), nurse group 43 (95% CI 24,
65 63). IPAQ-Walk minutes/week also increased: postal 57 (95% CI 2, 112), nurse 43 (95% CI -11, 97)
66 but IPAQ-MVPA minutes/week showed non-significant decreases: postal -11 (95% CI -65, 42), nurse
67 -34 (95% CI -87, 19).

68 **Conclusions:** Our results demonstrate the necessity of using a questionnaire focussing on the
69 activities being altered, as with IPAQ-Walk questions. Even then, the change in PA was estimated
70 with far less precision than with accelerometry. Accelerometry is preferred to self-report
71 measurement, minimising bias and improving precision when assessing effects of a walking
72 intervention.

73

74 Trial registration: ISRCTN, ISRCTN98538934. Registered 2 March 2012,

75 www.isrctn.com/ISRCTN98538934

76 **Keywords**

77 Walking; Intervention; Primary Care; MVPA; Accelerometry; IPAQ; GPPAQ

78

79

80 **BACKGROUND**

81 Adults who participate in regular physical activity (PA) and remain fit and active into later life have
82 fewer chronic health conditions, and are better able to maintain a healthy weight [1]. WHO, UK and
83 US aerobic PA guidelines for adults recommend at least 150 minutes weekly of moderate-to-
84 vigorous-physical-activity (MVPA) in bouts of at least 10 minutes, or 75 minutes of vigorous PA, or
85 a combination. Brisk walking (3 miles/hr or 5 km/hr) counts as MVPA[2] and for most people
86 approximates to 1000 steps in 10 minutes[3].

87

88 Self-report questionnaires are a quick, easy way to assess PA. Population surveys such as the Health
89 Survey for England (HSE)[4] and Sport England's "Active Lives Survey"[5] use self-completed
90 questionnaires and report estimates that around 60% of participants aged 16+ meet PA guidelines.
91 However, individuals often over-estimate their PA, particularly walking, on questionnaires compared
92 with accelerometry measures of MVPA[6-8]. Self-report questionnaires can thus lead to inflated
93 estimates of "active" individuals[9].

94

95 The International Physical Activity Questionnaire (IPAQ) short form[10] assesses 7-day recall of PA
96 in ≥ 10 minute bouts based on intensity (separating vigorous, moderate and walking activity) and
97 duration (days per week and minutes per day). The shorter General Practice Physical Activity
98 Questionnaire (GPPAQ)[11] does not provide a continuous measure of PA, but categorises
99 individuals as active or not. GPPAQ is used in the UK National Health Service (NHS) primary care
100 cardiovascular health checks[12]. Individuals classified as less than "active" are assumed not to be
101 meeting PA guidelines and are offered advice. In contrast, accelerometry is an objective PA measure,

102 providing information on step-counts and time spent in different PA intensities and is increasingly
103 being used in cross-sectional studies to study PA[13, 14]. Although accelerometers e.g. Actigraph are
104 not a gold standard for measuring PA, they have been shown to correlate well with doubly labelled
105 water to measure activity energy expenditure[15]. For the Actigraph GT3X accelerometer, standard
106 cut-points for accelerometer counts per minute (CPM) for different PA intensity categories have also
107 been defined, thus leading to assessment of time spent in different PA intensities: light 101-1951
108 CPM; moderate 1952-5724 CPM; vigorous ≥ 5725 CPM[16].

109

110 Longitudinal studies and trials which examine PA changes over time need valid, reliable PA
111 assessment methods. Both IPAQ-Short and accelerometry have been used separately to measure PA
112 change over time,[17-20] but only a few small studies have used both and compared change in
113 minutes of PA[21, 22]. Other studies have compared self-report PA minutes with either pedometer
114 steps[23, 24] or accelerometry counts[25] which are not directly comparable. The PACE-UP trial
115 offers the opportunity to directly compare change in PA minutes from accelerometry and IPAQ within
116 a large trial dataset. This study had the following objectives: to compare the trial treatment effects at
117 12 months (difference between intervention and control groups in the change in PA) using (i)
118 accelerometry minutes of MVPA and IPAQ minutes of moderate+vigorous activity and walking; (ii)
119 the percentage of “active” individuals classified by accelerometry, IPAQ and GPPAQ.

120

121 **METHODS**

122 **Background to the PACE-UP study**

123 The PACE-UP study is a three-arm parallel groups randomised controlled trial comparing a 3-month
124 pedometer-based walking intervention, delivered by post or with nurse support, to usual care[26].
125 Ethical approval was given by the London Research Ethics Committee (Hampstead) (12L/LO/0219),
126 trial registration ISRCTN 98538934. Adults aged 45-75 years from seven South-West London (UK)
127 General Practices (family practices) who self-reported as inactive were invited to take part. Following

128 a baseline assessment to assess eligibility, 1023 participants gave informed written consent and were
129 randomised into one of three groups: the Control group (n=338) received usual care; the Postal group
130 (n=339) received a pedometer, a 12-week personalised walking plan including behaviour change
131 techniques (e.g. goal setting, self-monitoring) designed to increase their walking and a step-count
132 diary through the post; the Nurse group (n=346) received these and were additionally offered three
133 individual practice nurse PA consultations. Randomisation was carried out at household level
134 allowing couples to take part together. The main trial outcomes were changes in accelerometry
135 measured average daily step-count and total weekly time in MVPA in ≥ 10 minute bouts between
136 baseline and 12 months. 956/1023 (93%) provided at least one day of accelerometry data at 12
137 months, >90% provided at least 5 days wear. The postal and nurse groups both significantly increased
138 their objective PA levels (step count and time in MVPA) compared with the control group, with no
139 difference between intervention groups at 12 months[27].

140

141 Participants wore a sealed accelerometer (GT3X, Actigraph LLC) over their hip for 7 consecutive
142 days at baseline, prior to randomization, and 12 months post-randomization. They also completed the
143 IPAQ Short form[10] and GPPAQ[11], both designed for self-completion, for the same 7-day periods
144 as they wore the accelerometer. Actilife software (v 6.6.0) was used to extract and reduce the
145 Actigraph data, ignoring runs of ≥ 60 minutes of zero counts[26], to provide daily steps counts and
146 time spent in ≥ 10 minute bouts of MVPA (≥ 1952 counts per minute, equivalent to ≥ 3 Metabolic
147 Equivalent (METs))[16]. When assessing ≥ 10 minute bout, the default “drop time” of 2 minutes was
148 used, which allows for a 2 minute interruption in bout activity. At baseline, all participants provided
149 ≥ 5 days of ≥ 540 minutes accelerometer wear-time. To limit attrition bias, those providing ≥ 1 day of
150 ≥ 540 minutes accelerometer wear time at 12 months were included in analyses. IPAQ questions focus
151 on time spent being physically active in the previous seven days in at least 10 minute bouts, including
152 PA at work, home, travelling and leisure. For each of vigorous and moderate PA and walking, there
153 are questions on the number of days and the duration on each of these days. GPPAQ questions ask

154 about PA at work and the type and weekly duration of leisure PA (physical exercise/sport, cycling,
155 walking, housework/childcare and gardening/DIY). Duration categories are None, <1 hour, 1-3 hours,
156 ≥ 3 hours.

157

158 **Study outcomes**

159 Accelerometry: The main accelerometry outcome was total weekly minutes of MVPA in ≥ 10 minute
160 bouts; a secondary outcome was total weekly minutes of MVPA, including MVPA in <10 minute
161 bouts. Binary variables were generated for each MVPA outcome to indicate 150 minutes of activity.

162 IPAQ: Total weekly minutes spent in each of vigorous PA, moderate PA and walking were calculated,
163 capped at a maximum of 3 hours/day or 21 hours/week, as recommended by the IPAQ coding
164 guidelines[28]. Two self-report PA measures were derived: total weekly minutes of vigorous +
165 moderate PA in bouts of ≥ 10 minutes, excluding walking (IPAQ-MVPA) and total weekly minutes
166 of walking in bouts of ≥ 10 minutes (IPAQ-Walk). We also report an additional outcome, IPAQ-Total
167 (IPAQ-MVPA + IPAQ-Walk), conceptually the same construct as accelerometry MVPA in ≥ 10
168 minute bouts. Binary variables were generated for each of these to indicate 150 minutes or more per
169 week of activity.

170 GPPAQ: The GPPAQ Physical Activity Index is a 4-level index ranging from “Inactive” through to
171 “Active”. “Active” individuals are achieving ≥ 3 hours (180 minutes) of MVPA per week including
172 work PA and leisure PA from physical exercise and cycling, but not including PA from walking,
173 housework/childcare or gardening. We defined a binary outcome, GPPAQ, to identify those
174 individuals classified as “Active” by the GPPAQ score. However, adults who are retired or not
175 working and who do no sport or cycling can never be classified as active, although they may achieve
176 MVPA guidelines through walking. Thus, a modified index, GPPAQ-Walk, was also derived, where
177 those who reported walking briskly for at least 3 hours per week were classified as “active”. . Previous
178 analysis of GPPAQ showed this modified index had improved sensitivity at identifying active
179 individuals compared with accelerometry data, but lower specificity in adults aged 60-75 years[29].

180

181 **Statistical analyses**

182 Analyses were carried out using Stata 14[30]. Multi-level regression models estimated treatment
183 effects for accelerometer, IPAQ and GPPAQ outcomes. The 12-month outcome was regressed on
184 baseline value, treatment group, age, gender, practice and month of baseline accelerometry as fixed
185 effects and household as a random effect in the multi-level model. (i) Linear regression was used for
186 weekly minutes of accelerometer MVPA, IPAQ-MVPA, IPAQ-Walk and IPAQ-Total; (ii) logistic
187 regression was used for the binary variables “active” from accelerometry, IPAQ and GPPAQ. The
188 distributions of change in PA for the four continuous outcomes were reasonably normally distributed,
189 as were the distributions of residuals from the models, allowing this method of analysis. Analyses
190 were restricted to those with complete data for all outcomes being compared: 833 at baseline and 655
191 for the longitudinal regression models. This ensured direct comparisons of the same group of
192 participants for each outcome. Sensitivity analyses used ≥ 180 minutes of accelerometer MVPA and
193 IPAQ outcomes, as the GPPAQ outcome is based on ≥ 180 minutes per week.

194

195 **RESULTS**

196 At baseline, accelerometry data were available on all participants and 989 (97%) returned IPAQ and
197 GPPAQ questionnaires. At 12 months, 956 (93%) participants provided at least one day of
198 accelerometry and 942 (92%) returned IPAQ and GPPAQ questionnaires. However, incomplete
199 answers on IPAQ and GPPAQ questions reduced the sample size to 833 at baseline and to 655 for
200 analyses of changes between baseline and 12 months. Study groups were balanced at baseline for the
201 833 with complete data with respect to age, gender, ethnicity and different health measures (Table 1).
202 One third of participants were male and two thirds were overweight or obese (Body Mass Index
203 $\geq 25\text{kg/m}^2$). Mean weekly minutes of accelerometer-MVPA were 317 (sd 151) for total MVPA and
204 98 (sd 103) for MVPA in ≥ 10 minute bouts. Self-reported mean weekly minutes were 174 (sd 279)
205 for IPAQ-MVPA, 315 (sd 310) for IPAQ-Walk, similar to total accelerometry MVPA and 489 (sd

206 453) for IPAQ-Total. Accelerometry data classified 23% of participants at baseline as “Active” i.e.
207 achieving ≥ 150 minutes of MVPA per week in ≥ 10 minute bouts (Table 1). In contrast, 35%, 66%
208 and 84% of participants self-reported ≥ 150 minutes per week of IPAQ-MVPA, IPAQ-Walk and
209 IPAQ-Total respectively. GPPAQ classified 12% of participants as active which increased to 28%
210 when walking was included.

211

212 **i) Comparison of estimated treatment effects using minutes of physical activity**

213 Both intervention groups showed statistically significant increases in accelerometer-MVPA, both in
214 bouts and total, compared with controls. Increases in accelerometer-MVPA bouts: postal group 42
215 minutes/week (95% CI 22 to 61), nurse group 43 (95% CI 24 to 63) (Table 2 and Figure 1a); increases
216 for total accelerometry MVPA were almost identical to accelerometer-MVPA in bouts but with wider
217 confidence intervals (Table 2 and Figure 1). Repeating the analysis using the IPAQ outcomes, IPAQ-
218 Walk showed positive increases, similar in magnitude to accelerometer-MVPA in the nurse group,
219 but with wider confidence intervals indicating less precision: postal group 57 minutes (95% CI 2 to
220 112), nurse group 43 (95% CI -11 to 97). IPAQ-MVPA showed non-significant decreases and IPAQ-
221 Total showed non-significant increases. The distribution of residuals from the regression models were
222 normally distributed for MVPA in bouts[27] and IPAQ outcomes (data not shown).

223

224 **ii) Comparison of estimated treatment effects using the binary variable “active”**

225 Similar patterns were found for the binary variable “active” for the different outcomes. Odds ratios
226 (ORs) for being “active” at 12 months (achieving ≥ 150 weekly minutes of MVPA in ≥ 10 minute
227 bouts) conditional on baseline “active” status were statistically significant for accelerometry-MVPA:
228 postal group 3.7 (95% CI 1.8 to 7.5) and nurse group 2.9 (95% CI 1.5 to 5.7) (Table 3). IPAQ-Walk
229 showed statistically significant OR for the postal group, 2.1 (95% CI 1.2 to 4.0) and borderline for
230 the nurse group, 1.7 (95% CI 1.0 to 3.0). Results were inconclusive for IPAQ-MVPA and IPAQ-
231 Total had increased ORs for both intervention groups, but only statistically significant for the nurse

232 group ORs for the two GPPAQ outcomes were close to 1.0 suggesting that GPPAQ was unable to
233 identify changes in the proportion classified as “active” (Table 3). Sensitivity analyses using ≥ 180
234 minutes of the accelerometer and IPAQ outcomes gave similar results.

235

236 **DISCUSSION**

237 The PACE-UP study was a walking intervention designed to increase individuals’ PA through a 3-
238 month programme, in particular MVPA in ≥ 10 minute bouts in line with current UK, WHO and US
239 PA guidelines[31-33]. We found statistically significant increases between baseline and 12 months
240 in accelerometer measured MVPA in ≥ 10 minute bouts for both intervention groups compared with
241 control. IPAQ-Walk showed a significant increase in the postal group and a non-significant increase
242 in the nurse group compared with control, but with less precision than with accelerometry.
243 IPAQ-MVPA showed non-significant decreases and IPAQ-Total non-significant increases in
244 intervention groups compared with controls. When considering the proportion of “active” individuals,
245 only accelerometry showed statistically significant increases for both intervention groups versus
246 controls. IPAQ-Walk and IPAQ-Total showed statistically significant increases for one intervention
247 group compared with controls (postal for IPAQ-Walk and nurse for IPAQ-Total), but borderline
248 effects for the other intervention group compared with controls. Neither IPAQ-MVPA nor GPPAQ
249 identified any change in the proportions categorised as “active” in intervention versus control groups.
250 Therefore, in terms of overall construct validity for assessing change in walking in a walking
251 intervention study, accelerometry has the greatest validity, followed by IPAQ-Walk. The other
252 measures have considerable disadvantages: IPAQ-MVPA and GPPAQ have very poor construct
253 validity; IPAQ-Total is measured with substantial imprecision and is unsuitable for assessing a
254 walking intervention as it includes IPAQ-MVPA.

255

256 Our study had several strengths. It was based on a large population-based sample of adults from seven
257 south-west London (UK) general practices (family practices), predominantly classified as inactive at

258 baseline. Accelerometry is an objective PA measure and measures walking accurately. We used
259 standard cut-points to define the different intensities of accelerometry activity and were thus able to
260 identify those bouts of walking which can be classified as MVPA. The main PACE-UP analysis[27]
261 showed that the increase in weekly steps in intervention groups relative to control group was
262 equivalent to the increase in weekly minutes of MVPA and this was all in ≥ 10 minute bouts, thus
263 demonstrating the effectiveness of the PACE-UP walking intervention. The two self-completed
264 questionnaires, IPAQ and GPPAQ, are standard questionnaires used to assess PA, and were
265 completed for the same seven days as for accelerometry, thus providing directly comparable estimates
266 of effect. The study achieved 93% accelerometry follow-up at 12 months, >90% of these with ≥ 5
267 days wear-time. Total weekly minutes of MVPA and total weekly minutes of walking (not including
268 MVPA) were easy to extract from IPAQ and provided a direct comparison with minutes of
269 accelerometer-MVPA. The increases in IPAQ-Walk minutes are similar to those for accelerometer-
270 MVPA suggesting that IPAQ can identify changes in walking minutes, although the wider confidence
271 intervals show the loss of precision from using IPAQ. At baseline, average IPAQ-Walk minutes were
272 similar to average total accelerometer-MVPA minutes rather than accelerometer-MVPA in ≥ 10
273 minute bouts. This is perhaps unsurprising, as the IPAQ walking questions ask for number of days
274 walking and duration on each day, and people may find it easier to report walking minutes as a
275 rounded number e.g. 30 or 45 minutes per day and which may include relative short walks of <10
276 minutes. GPPAQ is commonly used in UK general practice to assess an individual's PA. However,
277 it can underestimate PA amongst those not working or those whose main PA is walking, and this
278 study provided a further opportunity to evaluate our modified GPPAQ-Walk index[29]. We were
279 also able to estimate how well GPPAQ could identify individuals moving from "not active" to
280 "active" (assumed to be achieving PA guidelines). Finally, our method of analysis, regressing
281 outcome at 12 months on baseline values focusses on individual changes in activity while allowing
282 for regression to the mean. Cross-sectionally, the distributions of accelerometer-MVPA and IPAQ
283 measures are highly skewed leading many to present medians and interquartile ranges of activity at

284 different time points. However, change in activity is usually symmetric and reasonably normally
285 distributed, which our approach exploits. We were thus able to present mean changes in activity and
286 associated confidence intervals for both accelerometry and questionnaire measures, thus allowing for
287 a more informative comparison.

288

289 The study also had some important limitations. All of the PA measures (accelerometry, IPAQ and
290 GPPAQ) only measured PA levels for 7 days and it may be that participants were more likely to be
291 active or report being active in the week that their PA was being assessed, rather than at other times.
292 However, any such tendency would potentially affect all of the PA measures and would be true for
293 control participants as well as for those in the intervention group. IPAQ is difficult to complete and
294 thus unreliable if an individual's PA varies by day across the week. Although we had high return rates
295 at baseline and 12 months for the IPAQ and GPPAQ, 97% and 92% respectively, each IPAQ outcome
296 at baseline and 12 months had 20-25% missing or incomplete answers. Participants' comments on
297 the questionnaires described their confusion over how to interpret and answer the questions and many
298 questions were left blank. This reduced our sample size to 655 for comparisons with accelerometry
299 although this is still large compared with other studies[21-23]. The proportions of missing data were
300 similar across the three groups, but those with missing IPAQ data had lower mean
301 accelerometry-MVPA at baseline and 12 months than those with complete data. The accelerometry
302 effect sizes reported here (42-43 minutes) are also larger than for the full cohort (33-35 minutes)[27].
303 The limited options on GPPAQ for duration of PA, led to using ≥ 3 hours (180 minutes) for GPPAQ
304 "active" whereas the PA guidelines are ≥ 150 minutes. However, ORs from sensitivity analyses using
305 ≥ 180 minutes for accelerometry and IPAQ outcomes were similar to those using ≥ 150 minutes.
306 Although neither of our methods of measuring PA are considered a gold-standard, accelerometry has
307 the advantage of providing an objective time-stamped record of PA that does not rely on recall. It has
308 been validated as a measure of activity energy expenditure using doubly labelled water[15] and we
309 used standard cut-points in counts per minute to define MVPA.[16] Our findings that

310 accelerometer-MVPA and IPAQ-Walk provide similar estimates of change clearly support results
311 from the PACE-UP intervention which is aimed at increasing walking, but it is unknown if these
312 findings would be generalisable to other PA interventions.

313

314 Participants in the postal and nurse intervention groups were encouraged to increase their MVPA
315 through walking and the nurse group in particular were taught to recognise and classify different PA
316 intensities – vigorous, moderate, light, and sedentary. Thus they may have been more likely to
317 accurately report their PA on IPAQ at follow-up i.e. with less over-estimation of their PA levels,
318 which could explain the non-significant decreases in the treatment groups for IPAQ-MVPA from the
319 modelling.

320

321 **Comparison with other studies**

322 Our baseline data agree with other studies that individuals tend to over-estimate their PA on self-
323 report questionnaires compared with objective accelerometry, both time spent being physically
324 active[6] and proportions achieving PA guidelines[7]. Studies which have found better
325 correspondence between IPAQ and accelerometry cross-sectionally[34] have used total
326 accelerometer MVPA rather than MVPA in ≥ 10 minute bouts and a similar pattern is seen in our data
327 where baseline total accelerometer-MVPA minutes are similar to IPAQ-Walk minutes. However,
328 IPAQ questions ask about vigorous and moderate PA in ≥ 10 minute bouts and UK, WHO and US PA
329 guidelines are based on ≥ 150 minutes of MVPA per week in ≥ 10 minute bouts. In our trial, whilst
330 total accelerometry MVPA was much higher than accelerometry MVPA in ≥ 10 minute bouts, changes
331 in both measures were almost identical.

332

333 To our knowledge, this is the largest population-based trial to make direct comparisons of
334 accelerometry and self-report questionnaires to assess an individual's change in minutes of PA after
335 an intervention. All five studies we identified [21-25] which have attempted to compare longitudinal

336 changes in PA measured using IPAQ compared to objective measures have limitations. Three studies
337 recruited less than 100 subjects[21-23]. One study was observational[21], one had no control
338 group[22] and one was a weight loss intervention rather than PA intervention[24]. One study was
339 comparing IPAQ with pedometer steps[23] and another with accelerometer counts[25] making direct
340 comparison of minutes of physical activity between IPAQ and accelerometry difficult. Whilst our
341 study compares measures using different constructs, we were able to compare time spent in MVPA
342 and time spent walking, both in minutes per week. Three studies present distribution of PA measures
343 at baseline and follow-up, but provided no estimate of the distribution of change[21, 24, 25] Our
344 findings do agree with two of the small studies. Nicaise et al[22] followed up one group of women,
345 but with no control group, and found median changes in IPAQ Walking minutes were similar to
346 median changes in accelerometer MVPA minutes. Baker et al[23] compared IPAQ PA minutes with
347 pedometer steps, and argue that the increase in step counts in the intervention group was comparable
348 to the increase in leisure time walking reported on IPAQ, although they report mean differences for
349 pedometer steps and median differences for IPAQ data.

350

351 GPPAQ is used in UK primary care to help identify those not achieving PA guidelines during UK
352 NHS Health Checks [12]. GPPAQ guidance recommends repeating it annually on those at increased
353 cardiovascular risk [11], however our study suggests that it is poor at identifying those individuals
354 who have increased their PA to current guideline levels. In addition, the binary nature of this outcome
355 fails to recognise modest, but important, increases in PA made by inactive individuals. We have also
356 confirmed our previous findings [29] that, compared with objective accelerometry, GPPAQ
357 underestimates the proportion of “active” individuals and our modified index GPPAQ-Walk classifies
358 slightly more as “active”.

359

360 **CONCLUSIONS**

361 We have demonstrated that neither GPPAQ nor IPAQ-MVPA provide a valid estimate of change in
362 a walking intervention trial compared with accelerometry measures. Moreover, we have shown that
363 although IPAQ-Walk produces an estimate of change comparable with that from accelerometry
364 MVPA in ≥ 10 minute bouts, the IPAQ-Walk estimate had considerably less precision. Missing data
365 were also an issue with the self-report IPAQ. This has implications for future trials. Studies may need
366 to use IPAQ to assess changes in walking if they are not able to use accelerometry. If this is the case,
367 they should focus particularly on the walking questions and will need to be larger to be adequately
368 powered, although they will still lack information on intensity of any changes that occur. In
369 conclusion, accelerometry is preferred to self-report measures in assessing the effects of a walking
370 intervention, as it avoids recall bias and improves precision.

371

372 **LIST OF ABBREVIATIONS**

373 PA: Physical Activity

374 MVPA: Moderate-to-vigorous physical activity

375 IPAQ: International Physical Activity Questionnaire

376 GPPAQ: General Practice Physical Activity Questionnaire

377 NHS: UK National Health Service

378 95% CI: 95% Confidence Interval

379 sd: Standard deviation

380 OR: Odds ratio

381

382

383 **DECLARATIONS**

384 **Ethics approval and consent**

385 Ethics approvals were obtained from NRES Committee London – Hampstead REC reference:
386 12/LO/0219. Written consent was obtained from all participants.

387

388 **Consent for publication**

389 Not applicable

390

391 **Availability of data**

392 There are restrictions on the availability of the data for this study due to the signed consent agreements
393 around data security, which only allow access to external researchers for research monitoring
394 purposes. Requestors wishing to access the data for the purposes of replicating or checking analyses
395 can apply to Research Data Management at St George's University of London
396 researchdata@sgul.ac.uk.

397

398 **Competing interests**

399 The authors declare that they have no competing interests.

400

401 **Funding**

402 The research was conducted as part of the main randomised controlled trial of PACE-UP which was
403 funded by the Health Technology Assessment Programme, National Institute of Health Research UK,
404 (project number HTA 10/32/02, ISRCTN98538934) and will be published in full in Health
405 Technology Assessment. The funders had no role in study design (beyond the commissioned call
406 outline), data collection and analysis, decision to publish, or preparation of the manuscript.

407

408

409 **Author Contributions**

410 TH, DGC, ESL and SA conceived the idea for the paper. TH, DGC, SMK, CRV, PHW, MU, SI, UE
411 and JFR were trial investigators and designed and were awarded funding for the trial. TH was trial
412 Principal Investigator and had overall responsibility for the execution of the project. JI and SDW

413 recruited general practices to the trial. CF was trial manager and oversaw data collection for the trial.
414 ESL and DGC designed the analyses and ESL conducted the analyses for this paper. The manuscript
415 was prepared by TH, ESL and DGC with input from all of the other authors. All of the author team
416 reviewed and approved the manuscript prior to submission.

417

418 **Acknowledgements**

419 We would like to thank the South-West London (UK) general practices, their practice nurses who
420 supported this study, and all the patients from these practices who participated: Upper Tooting Road
421 Practice, Tooting; Chatfield Practice, Battersea; Wrythe Green Practice, Carshalton; Francis Grove
422 Practice, Wimbledon; Putneymead Practice Putney; Heathfield Practice Putney; and Cricket Green
423 Practice, Mitcham.

424 Disclaimer: the views and opinions expressed therein are those of the authors and do not necessarily
425 reflect those of the Health Technology Assessment (HTA) Programme, National Institute for Health
426 Research (NIHR) National Health Service, or the Department of Health.

427 The results of the study are presented clearly, honestly and without fabrication, falsification or
428 inappropriate data manipulation.

429

430

431 **REFERENCES**

- 432 1. Lee, I.M., Shiroma, E.J., Lobelo, F., Puska, P., et al., Effect of physical inactivity on major
433 non-communicable diseases worldwide: an analysis of burden of disease and life
434 expectancy. *Lancet*, 2012. 380(9838):219-29.
- 435 2. Morris, J.N. and Hardman, A.E., Walking to health. *Sports Med*, 1997. 23(5):306-32.
- 436 3. Tudor-Locke, C., Craig, C.L., Brown, W.J., Clemes, S.A., et al., How many steps/day are
437 enough? For adults. *Int J Behav Nutr Phys Act*, 2011. 8:79.
- 438 4. The Health and Social Care Information Centre, Health Survey for England 2016. 2017.
- 439 5. Sport England, Active Lives Survey. 2017: UK.
- 440 6. Lee, P.H., Macfarlane, D.J., Lam, T.H., and Stewart, S.M., Validity of the International
441 Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. *Int J Behav*
442 *Nutr Phys Act*, 2011. 8:115.
- 443 7. Troiano, R.P., Berrigan, D., Dodd, K.W., Masse, L.C., et al., Physical activity in the United
444 States measured by accelerometer. *Med Sci Sports Exerc*, 2008. 40(1):181-8.
- 445 8. The Health and Social Care Information Centre, Health Survey for England 2008. 2009.
- 446 9. Harris, T.J., Owen, C.G., Victor, C.R., Adams, R., et al., A comparison of questionnaire,
447 accelerometer, and pedometer: measures in older people. *Med Sci Sports Exerc*, 2009.
448 41(7):1392-402.
- 449 10. The IPAQ group. International Physical Activity Questionnaire. [Accessed: 21/01/2014];
450 Available from: <https://sites.google.com/site/theipaq/home>.
- 451 11. Department of Health, General practice physical activity questionnaire (GPPAQ). 2013.
- 452 12. NHS. NHS Health Check. [Accessed: 13/10/2017]; Available from:
453 <http://www.healthcheck.nhs.uk/>.
- 454 13. Sardinha, L.B., Magalhaes, J.P., Santos, D.A., and Judice, P.B., Sedentary Patterns, Physical
455 Activity, and Cardiorespiratory Fitness in Association to Glycemic Control in Type 2
456 Diabetes Patients. *Front Physiol*, 2017. 8:262.

- 457 14. Chudyk, A.M., McKay, H.A., Winters, M., Sims-Gould, J., et al., Neighborhood
458 walkability, physical activity, and walking for transportation: A cross-sectional study of
459 older adults living on low income. *BMC Geriatr*, 2017. 17(1):82.
- 460 15. Plasqui, G. and Westerterp, K.R., Physical activity assessment with accelerometers: an
461 evaluation against doubly labeled water. *Obesity (Silver Spring)*, 2007. 15(10):2371-9.
- 462 16. Freedson, P.S., Melanson, E., and Sirard, J., Calibration of the Computer Science and
463 Applications, Inc. accelerometer. *Med Sci Sports Exerc*, 1998. 30(5):777-81.
- 464 17. Fassier, P., Zelek, L., Partula, V., Srour, B., et al., Variations of physical activity and
465 sedentary behavior between before and after cancer diagnosis: Results from the prospective
466 population-based NutriNet-Sante cohort. *Medicine (Baltimore)*, 2016. 95(40):e4629.
- 467 18. Barr-Anderson, D.J., Flynn, J.I., Dowda, M., Taverno Ross, S.E., et al., The Modifying
468 Effects of Race/Ethnicity and Socioeconomic Status on the Change in Physical Activity
469 From Elementary to Middle School. *J Adolesc Health*, 2017.
- 470 19. Demeyer, H., Louvaris, Z., Frei, A., Rabinovich, R.A., et al., Physical activity is increased
471 by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre
472 randomised controlled trial. *Thorax*, 2017. 72(5):415-423.
- 473 20. Ekelund, U., Kolle, E., Steene-Johannessen, J., Dalene, K.E., et al., Objectively measured
474 sedentary time and physical activity and associations with body weight gain: does body
475 weight determine a decline in moderate and vigorous intensity physical activity? *Int J Obes*
476 (Lond), 2017. 41(12):1769-1774.
- 477 21. Horne, D., Kehler, D.S., Kaoukis, G., Hiebert, B., et al., Impact of physical activity on
478 depression after cardiac surgery. *Can J Cardiol*, 2013. 29(12):1649-56.
- 479 22. Nicaise, V., Crespo, N.C., and Marshall, S., Agreement between the IPAQ and
480 accelerometer for detecting intervention-related changes in physical activity in a sample of
481 Latina women. *J Phys Act Health*, 2014. 11(4):846-52.

- 482 23. Baker, G., Gray, S.R., Wright, A., Fitzsimons, C., et al., The effect of a pedometer-based
483 community walking intervention "Walking for Wellbeing in the West" on physical activity
484 levels and health outcomes: a 12-week randomized controlled trial. *Int J Behav Nutr Phys*
485 *Act*, 2010. 7:51.
- 486 24. Fuller, N.R., Williams, K., Shrestha, R., Ahern, A.L., et al., Changes in physical activity
487 during a weight loss intervention and follow-up: a randomized controlled trial. *Clin Obes*,
488 2014. 4(3):127-35.
- 489 25. Opdenacker, J., Boen, F., Vanden Auweele, Y., and De Bourdeaudhuij, I., Effectiveness of a
490 lifestyle physical activity intervention in a women's organization. *J Womens Health*
491 *(Larchmt)*, 2008. 17(3):413-21.
- 492 26. Harris, T., Kerry, S.M., Victor, C.R., Shah, S.M., et al., PACE-UP (Pedometer and
493 consultation evaluation--UP)--a pedometer-based walking intervention with and without
494 practice nurse support in primary care patients aged 45-75 years: study protocol for a
495 randomised controlled trial. *Trials*, 2013. 14:418.
- 496 27. Harris, T., Kerry, S.M., Limb, E.S., Victor, C.R., et al., Effect of a Primary Care Walking
497 Intervention with and without Nurse Support on Physical Activity Levels in 45- to 75-Year-
498 Olds: The Pedometer And Consultation Evaluation (PACE-UP) Cluster Randomised
499 Clinical Trial. *PLoS Med*, 2017. 14(1):e1002210.
- 500 28. The IPAQ group. Guidelines for data processing and analysis of the International Physical
501 Activity Questionnaire (IPAQ) - Short and Long forms. [Accessed: 15/10/2015]; Available
502 from: <https://sites.google.com/site/theipaq/scoring-protocol>.
- 503 29. Ahmad, S., Harris, T., Limb, E., Kerry, S., et al., Evaluation of reliability and validity of the
504 General Practice Physical Activity Questionnaire (GPPAQ) in 60-74 year old primary care
505 patients. *BMC Fam Pract*, 2015. 16:113.
- 506 30. StataCorp, Stata Statistical Software: Release 14. 2015, StataCorp LLC:
507 <http://www.stata.com/>.

- 508 31. Department of Health, Start Active, Stay Active: A report on physical activity for health
509 from the four home countries' Chief Medical Officers. 2011,
510 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216370/dh_1
511 [28210.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216370/dh_1).
- 512 32. World Health Organisation, Global Recommendations on Physical Activity for Health.
513 2010: Geneva: World Health Organisation. p. 58.
- 514 33. US Department of Health and Human Services, 2008 Physical Activity Guidelines for
515 Americans. 2008: Washington: Office of Disease Prevention and Health Promotion. p. 76.
- 516 34. Ekelund, U., Sepp, H., Brage, S., Becker, W., et al., Criterion-related validity of the last 7-
517 day, short form of the International Physical Activity Questionnaire in Swedish adults.
518 Public Health Nutr, 2006. 9(2):258-65.

519

520

521 **Figure captions**

522 Figure 1. Treatment effects and 95% confidence intervals for change in minutes of physical activity
523 measured by accelerometry, IPAQ-MVPA, IPAQ-Walk and IPAQ-Total.

524

525

526

527

528

529

530 **Table 1. Demographic, health, physical characteristics and physical activity at baseline.**

531

	All groups	Control	Postal	Nurse
	(N=833)	(N=279)	(N=270)	(N=284)
	n (%)	n (%)	n (%)	n (%)
Age at randomisation				
45-54 years	280 (34%)	87 (31%)	94 (35%)	99 (35%)
55-64 years	315 (38%)	111 (40%)	98 (36%)	106 (37%)
65-75 years	238 (29%)	81 (29%)	78 (29%)	79 (28%)
Sex: Male	304 (36%)	98 (35%)	104 (39%)	102 (36%)
Ethnicity				
White	654 (81%)	212 (79%)	222 (85%)	220 (80%)
Black / African / Caribbean / Black British	77 (10%)	25 (9%)	21 (8%)	31 (11%)
Asian / Asian British	54 (7%)	21 (8%)	14 (5%)	19 (7%)
Other, incl mixed	19 (2%)	10 (4%)	4 (2%)	5 (2%)
General health: Very good or good	679 (83%)	223 (81%)	230 (88%)	226 (82%)
Chronic diseases				
None	321 (39%)	109 (39%)	112 (42%)	100 (36%)
1-2	436 (53%)	153 (55%)	133 (50%)	150 (54%)
≥3	61 (7%)	14 (5%)	20 (8%)	27 (10%)
Self-reported pain: Yes	566 (69%)	185 (67%)	191 (72%)	190 (69%)
Limiting long-standing illness	174 (21%)	60 (22%)	55 (21%)	59 (21%)
Townsend Disability score				
None (0)	491 (60%)	159 (58%)	158 (59%)	174 (62%)
Slight or some disability (1-6)	305 (37%)	103 (37%)	104 (39%)	98 (35%)
Appreciable or severe disability (7-18)	24 (3%)	13 (5%)	4 (2%)	7 (3%)

532

Physical characteristics	n (%)	n (%)	n (%)	n (%)
Overweight/obese: BMI \geq 25kg/m ²	544 (65%)	184 (66%)	173 (64%)	187 (66%)
	Mean (sd)	Mean (sd)	Mean (sd)	Mean (sd)
Fat mass (kg)	26 (11)	26 (10)	26 (11)	26 (11)
Accelerometry data	Mean (sd)	Mean (sd)	Mean (sd)	Mean (sd)
Adjusted baseline step count per day	7550 (2670)	7528 (2685)	7480 (2583)	7638 (2744)
Total weekly mins MVPA in \geq 10 min bouts	98 (103)	91 (100)	97 (94)	106 (113)
Total weekly mins MVPA	317 (151)	316 (152)	311 (145)	322 (154)
Daily wear time (minutes)	792 (79)	791 (73)	789 (79)	796 (84)
International Physical Activity Questionnaire (IPAQ)				
IPAQ-MVPA: Weekly mins of moderate PA + vigorous PA in \geq 10 min bouts	174 (279)	194 (310)	159 (266)	167 (259)
IPAQ-Walk: Weekly minutes of walking in \geq 10 min bouts	315 (310)	323 (327)	316 (326)	307 (275)
IPAQ-Total: Weekly minutes of moderate PA+vigorous PA+walking in $>$ -10 min bouts	489 (453)	518 (501)	475 (457)	474 (395)
Proportions of "active" individuals ¹	n (%)	n (%)	n (%)	n (%)
Accelerometry				
150 weekly mins MVPA in \geq 10 min bouts	190 (23%)	57 (21%)	58 (22%)	75 (27%)
International Physical Activity Questionnaire (IPAQ)				
150 weekly mins of IPAQ-MVPA	286 (35%)	99 (36%)	86 (32%)	101 (36%)
150 weekly mins of IPAQ-Walk	540 (66%)	176 (64%)	173 (65%)	191 (68%)
150 weekly mins of IPAQ-Total	690 (84%)	227 (82%)	226 (85%)	237 (84%)
General Practice Physical Activity Questionnaire (GPPAQ)				
GPPAQ: "Active" \geq 180 mins PA per week	101 (12%)	38 (14%)	33 (12%)	30 (11%)

GPPAQ-Walk: "Active" ≥ 180 mins PA per week including walking at brisk/fast pace 229 (28%) 82 (30%) 71 (27%) 76 (27%)

533

534 **Footnotes**

535 1 Proportions of "active" individuals are based on 276, 265 and 281 participants in Control, Postal and Nurse
536 groups respectively

Table 2. Physical activity outcomes (total weekly minutes) at baseline and 12 months for accelerometry and IPAQ

	Group summary data						Treatment effects			
	Control group (n=231)		Postal group (n=207)		Nurse group (n=217)		Postal vs Control		Nurse vs Control	
	Baseline	12 months	Baseline	12 months	Baseline	12 months	Effect	<i>p</i> -value	Effect	<i>p</i> -value
	Mean (sd)	Mean (sd)	Mean (sd)	Mean (sd)	Mean (sd)	Mean (sd)	(95% CI)		(95% CI)	
Accelerometry outcomes										
Daily step count	7572 (2738)	7402 (2724)	7691 (2560)	8233 (3076)	7487 (2738)	8146 (3224)	804 (426, 1181)	<0.001	837 (463, 1211)	<0.001
MVPA in ≥10 min bouts (weekly minutes)	95 (103)	97 (101)	107 (95)	144 (128)	107 (114)	146 (149)	42 (22, 61)	<0.001	43 (24, 63)	<0.001
Total MVPA (weekly minutes)	319 (155)	330 (160)	329 (143)	377 (173)	317 (157)	367 (189)	43 (20, 65)	<0.001	41 (18, 63)	<0.001
IPAQ outcomes										
IPAQ-MVPA (weekly minutes)	188 (300)	222 (343)	171 (285)	200 (288)	165 (249)	180 (300)	-11 (-65, 42)	0.68	-34 (-87, 19)	0.21
IPAQ-Walk (weekly minutes)	336 (332)	356 (335)	331 (336)	398 (332)	286 (262)	365 (309)	57 (2, 112)	0.04	43 (-11, 97)	0.12

IPAQ-Total (weekly minutes)	525 (494)	578 (520)	502 (481)	598 (479)	450 (365)	545 (456)		46	0.26	14	0.74
								(-34, 126)		(-66, 93)	

539 **Table 3. Physical activity outcomes (“active”) at baseline and 12 months for accelerometry, IPAQ and GPPAQ**

	Group summary data						Treatment effects			
	Control group (n=228)		Postal group (n=205)		Nurse group (n=213)		Postal vs Control		Nurse vs Control	
	Baseline	12 months	Baseline	12 months	Baseline	12 months	OR	p-value	OR	p-value
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	(95% CI)		(95% CI)	
Accelerometry										
MVPA bouts: 150 minutes	54 (24%)	47 (21%)	53 (26%)	83 (40%)	55 (26%)	79 (37%)	3.7	<0.001	2.9	0.002
							(1.8, 7.5)		(1.5, 5.7)	
MVPA total: 150 minutes	199 (87%)	200 (88%)	180 (88%)	185 (90%)	183 (86%)	193 (91%)	1.7	0.24	1.7	0.24
							(0.7, 3.9)		(0.7, 3.8)	
IPAQ										
IPAQ-MVPA: 150 minutes	81 (36%)	90 (39%)	68 (33%)	89 (43%)	77 (36%)	76 (36%)	1.4	0.38	0.6	0.27
							(0.6, 3.3)		(0.3, 1.4)	
IPAQ-Walk: 150 minutes	148 (65%)	156 (68%)	136 (66%)	161 (79%)	137 (64%)	162 (76%)	2.1	0.01	1.7	0.05
							(1.2, 4.0)		(1.0, 3.0)	
IPAQ-Total: 150 minutes	190 (83%)	189 (83%)	177 (86%)	182 (89%)	178 (84%)	194 (91%)	1.8	0.07	2.3	0.02
							(0.9, 3.5)		(1.1, 4.6)	
GPPAQ										

PA Index: Active \geq 180 mins	28 (12%)	37 (16%)	31 (15%)	37 (18%)	24 (11%)	28 (13%)	1.1	0.83	0.8	0.50
PA per week							(0.6, 2.1)		(0.4, 1.6)	
PA Index incl walking:	66 (29%)	77 (34%)	62 (30%)	74 (36%)	59 (28%)	70 (33%)	1.1	0.66	1.0	0.89
Active \geq 180 mins PA per week including walking at brisk/fast pace							(0.7, 1.9)		(0.6, 1.8)	

540

541

Postal vs Control

Acc-MVPA bouts

Acc-MVPA total

IPAQ-MVPA

IPAQ-Walk

IPAQ-Total

Nurse vs Control

Acc-MVPA bouts

Acc-MVPA total

IPAQ-MVPA

IPAQ-Walk

IPAQ-Total

